



## **Editas Medicine to Participate in Investor Conferences in October**

October 3, 2017

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in New York in October. Details are as follows:

Chardan Gene Therapy Conference  
*Tuesday, October 10*

- Manufacturing Panel | 12:15 p.m. ET
- Fireside Chat | 3:45 p.m. ET

Jefferies Gene Technology Investor Summit  
*Thursday, October 12*

- Presentation | 1:20 p.m. ET

A live webcast of the events will be available on the Investors & Media section of the Editas Medicine website at [www.editasmedicine.com](http://www.editasmedicine.com). An archived replay will be available for approximately 30 days following the events.

### **About Editas Medicine**

Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

### **Media Contact**

Cristi Barnett  
Editas Medicine, Inc.  
(617) 401-0113  
[cristi.barnett@editasmed.com](mailto:cristi.barnett@editasmed.com)

### **Investor Contact**

Mark Mullikin  
Editas Medicine, Inc.  
(617) 401-9083  
[mark.mullikin@editasmed.com](mailto:mark.mullikin@editasmed.com)



Editas Medicine